OR WAIT 15 SECS
Rubicon Genomics has announced that it has signed a supply agreement with Kreatech Diagnostics for use of Rubicon?s Omniplex-D whole genome amplification technology.
Rubicon Genomics has announced that it has signed a supply agreement with Kreatech Diagnostics for use of Rubicon’s Omniplex-D whole genome amplification technology.
Under the terms of the agreement, Rubicon will provide proprietary reagents which will incorporate elements of its Omniplex amplification technology to Kreatech for use in the manufacture of Kreatech’s Poseidon fluorescence in situ hybridization probes.
James Koziarz, CEO of Rubicon, commented, “Collaborating with a diverse group of industry leaders is a key part of Rubicon's strategy, and we are very pleased to be working with Kreatech, which offers the broadest commercial portfolio of high quality FISH probes available today."
Herman Volkers, CEO of Kreatech, said, “Use of Rubicon's proprietary pre-analytical amplification reagents during the production process contributes to achievement of this superior performance; therefore we are pleased to conclude this renewed supply agreement with Rubicon Genomics.”